By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
VTU Technology And Boehringer Ingelheim Strengthen Their Global Microbial Technology Collaboration 4/27/2016 9:05:27 AM
Boehringer Ingelheim Reports A Successful Financial Year 2015 4/19/2016 8:23:12 AM
Boehringer Ingelheim Exercises Option On Second Oncology Target Using Oxford BioTherapeutics' OGAP System 4/18/2016 9:11:21 AM
Boehringer Ingelheim Release: FDA Approves Gilotrif (Afatinib) As New Oral Treatment Option For Patients With Squamous Cell Carcinoma Of The Lung 4/18/2016 7:02:37 AM
Boehringer Ingelheim Release: Head-To-Head Study Demonstrating Gilotrif (Afatinib) Significantly Improved Clinical Outcomes Compared To Iressa (Gefitinib) In EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Published In The Lancet Oncology 4/13/2016 6:18:53 AM
Boehringer Ingelheim Release: Lancet Publication: New Analysis Demonstrates Only Small Minority Of Severe/Very Severe COPD Patients May Benefit From Adding ICS To SPIRIVA HANDIHALER (Tiotropium Bromide Inhalation Powder) + LABA Therapy 4/8/2016 7:24:25 AM
Centrexion Expands Pain Pipeline With Acquisition Of Three New Analgesic Candidates From Boehringer Ingelheim 3/30/2016 9:42:08 AM
Amal Therapeutics Raises CHF 3 Million In A Series A Financing Round Led By Boehringer Ingelheim Venture Fund 3/30/2016 8:54:41 AM
FDA Approves Supplemental New Drug Application (sNDA) For Boehringer Ingelheim's STIOLTO RESPIMAT For COPD Health-Related Quality Of Life 3/29/2016 6:26:17 AM
Zai Lab Signs Up Boehringer Ingelheim For China Manufacturing Of mAb 3/28/2016 1:59:34 PM